Vanguard Fiduciary Trust’s TransCode Therapeutics RNAZ Stock Holding History

Vanguard Fiduciary Trust’s Portfolio RNAZ Stock Details RNAZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$18.5K	Hold	2,982	–	–	﹤0.01%	4003
2026 Q1	$25.7K	Buy	+2,982	New	+$27.8K	﹤0.01%	3919

Other funds holding RNAZ

YAG

Yorkville Advisors Global Mountainside, New Jersey $86.2M AUM 41.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Mercer Global Advisors Denver, Colorado $80B AUM 26.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Vanguard Fiduciary Trust's RNAZ Position: Q2 2026 in Review

Vanguard Fiduciary Trust held its TransCode Therapeutics (RNAZ) position steady in Q2 2026 at 2,982 shares worth $18.5K. The position accounts for ﹤0.01% of the portfolio, ranked #4003.

Vanguard Fiduciary Trust first reported a position in RNAZ in Q1 2026 and has held it in 2 quarters since. The position peaked at $25.7K in Q1 2026. 8 funds tracked by Wall St. Rank hold RNAZ as of Q2 2026.

Vanguard Fiduciary Trust held 2,982 shares of TransCode Therapeutics worth $18.5K as of Q2 2026.
Vanguard Fiduciary Trust left its TransCode Therapeutics share count unchanged in Q2 2026.
TransCode Therapeutics made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #4003 holding.
Vanguard Fiduciary Trust first reported a position in TransCode Therapeutics in Q1 2026 and has held it in 2 quarters since.
Vanguard Fiduciary Trust's TransCode Therapeutics position peaked at $25.7K in Q1 2026.
8 funds tracked by Wall St. Rank held TransCode Therapeutics as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.